Investment Rating - The report maintains a "Buy" rating for China Life Insurance (601628) [2][8] Core Views - The company's performance for 2025 met expectations, with a year-on-year increase in net profit attributable to shareholders of 44.1% to 154.1 billion yuan, although the growth rate decreased by 16.5 percentage points compared to the previous three quarters due to significant increases in the second half of 2025 and capital market fluctuations in the fourth quarter [5] - The company has increased its allocation to equity investments in the secondary market to 17%, with a total investment asset scale of 7.42 trillion yuan, reflecting a year-on-year growth of 12.3% [7] - The report projects a downward adjustment in profit forecasts for 2026-2028, estimating net profits of 164.24 billion yuan, 186.28 billion yuan, and 222.85 billion yuan respectively, due to increased capital market volatility and geopolitical risks [8] Financial Data Summary - For 2025, the company reported a total revenue of 615.68 billion yuan, with a year-on-year growth rate of 16.48% [9] - The net profit attributable to shareholders for 2025 was 154.08 billion yuan, reflecting a year-on-year growth of 44.09% [9] - The earnings per share for 2025 is projected at 5.45 yuan, with a price-to-earnings ratio of 7.24 [9] Investment Analysis - The company has shown a robust increase in new business value (NBV), with a year-on-year growth of 35.7% to 45.75 billion yuan, slightly exceeding expectations [6] - The contribution from bancassurance has significantly increased, with a year-on-year growth of 169.3% in non-individual insurance channel NBV [10] - The report highlights a strategic shift towards equity investments, with the proportion of equity and fund allocations increasing by 4.7 percentage points to 16.9% [7]

Core Viewpoint - China Life Insurance Company reported a net profit growth of 44.1% year-on-year for 2025, but experienced a net loss in the fourth quarter, attributed to structural adjustments in the capital market affecting its stock and fund holdings. The management emphasized that these fluctuations are mostly temporary and do not reflect the company's long-term operational trends [3][4]. Group 1: Financial Performance - For the first three quarters of 2025, China Life achieved a net profit attributable to shareholders of 167.8 billion yuan, a year-on-year increase of 60.5%. The total net profit for the year was 154.1 billion yuan, reflecting a growth of 44.1% [3]. - The total investment income for 2025 reached 387.7 billion yuan, an increase of 79.4 billion yuan compared to the same period in 2024. The total investment return rate was 6.09%, up by 59 basis points from the previous year [4]. Group 2: Investment Strategy - As of December 31, 2025, China Life's investment assets amounted to 7.42 trillion yuan, representing a growth of 12.3% from the end of 2024. The allocation ratio of stocks and funds (excluding money market funds) increased from 12.18% at the end of 2024 to 16.89%, indicating a strategic increase in equity investments [4]. - The company is closely monitoring global geopolitical risks, particularly those arising from the US-Iran conflict, although the impact on its overall assets is minimal due to the small scale of its overseas asset allocation. The company plans to leverage its long-term capital stability to dynamically adjust its asset allocation strategy [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has demonstrated significant results from its product diversification transformation, with dividends achieving high growth for two consecutive years [1] - The company’s net profit attributable to shareholders for 2025 is projected at 154.1 billion yuan, representing a year-on-year increase of 44% [1] - The company’s investment performance is expected to benefit from equity allocation, while the liability side is anticipated to maintain healthy growth in the medium to long term [1] Financial Performance Summary - Total premium income for 2025 reached 729.9 billion yuan, up 8.7% year-on-year, with new business premiums at 234.1 billion yuan, increasing by 9.3% [2] - The company achieved a new business value (NBV) of 45.8 billion yuan in 2025, reflecting a year-on-year growth of 36% [2] - The investment assets of the company reached 7.42 trillion yuan in 2025, a 12% increase year-on-year, with net investment income of 193.8 billion yuan, down 1% from the previous year [3] Financial Projections - The company’s projected net profit for 2026 is 168 billion yuan, with a year-on-year growth of 9%, and for 2027, it is expected to reach 177.6 billion yuan, growing by 5.8% [1][4] - The embedded value (EV) at the end of 2025 is estimated at 1.47 trillion yuan, a 4.8% increase from the beginning of the year [1] - The company plans to distribute a dividend of 0.856 yuan per share for the year, which is a 32% increase year-on-year, resulting in a static dividend yield of 2.2% at the current stock price [1]

Investment Rating - The report maintains a "Buy" rating for China Life Insurance (601628) with a target price of 53.41 CNY [6][13]. Core Insights - The company achieved a net profit growth of 44.1% year-on-year for 2025, with net assets increasing by 16.8% from the beginning of the year, driven by improvements in both insurance and investment performance [3][13]. - The report highlights a significant increase in the proportion of equity investments, with total investment assets reaching 7.4 trillion CNY, a 12.3% year-on-year increase, and the share of stocks and funds rising to 16.9%, up 4.7% [13]. - The new business value (NBV) grew by 35.7% in 2025, with individual insurance and bancassurance segments showing year-on-year increases of 25.5% and 169.3%, respectively [13]. Financial Summary - Revenue for 2025 is projected at 615.678 billion CNY, reflecting a 16% increase from 2024 [5]. - The net profit attributable to shareholders is expected to reach 154.078 billion CNY in 2025, marking a 44% increase compared to 2024 [5]. - Earnings per share (EPS) for 2025 is forecasted at 5.45 CNY, with a projected net asset return rate of 26% [5][14]. Business Performance - The report indicates that the company's insurance service revenue is expected to grow to 214.136 billion CNY in 2025, with a slight increase in insurance service expenses [14]. - The investment income is projected to rise to 198.457 billion CNY in 2025, benefiting from improved market conditions [14]. - The company’s solvency ratios are reported at 128.8% for core solvency and 174.0% for comprehensive solvency, although these figures have decreased year-on-year [13].

Investment Rating - The report assigns a "Buy-A/Buy-H" rating for the company [3] Core Views - The company's performance and value are both strong, with dividend growth exceeding expectations [1] - The net profit for 2025 increased by 44.1% year-on-year, driven by market upturns and increased equity allocation [12][44] - The new business value (NBV) grew by 35.7% year-on-year, supported by a strong demand for savings products and improved distribution channels [30][46] Financial Forecast - Embedded Value (CNY million) is projected to grow from 1,401,146 in 2024 to 1,960,695 in 2028, with a growth rate of 11.2% in 2024 [2] - Net profit is expected to reach 106,935 million in 2024, with a significant increase of 131.56% year-on-year [2] - Earnings per share (EPS) is forecasted to be 3.78 in 2024, increasing to 6.01 by 2028 [2] Performance Analysis - The company's total investment assets reached 7.42 trillion, a 12.3% increase year-on-year, with a notable rise in equity investments [22] - The total investment return for 2025 was 6.1%, reflecting a 0.6 percentage point increase from the previous year [25] - The company’s net investment yield was 3% in 2025, supported by a higher allocation to high-dividend assets [25] Value Analysis - The NBV for 2025 is projected at 45,752 million, with a year-on-year increase of 35.7% [2][30] - The company's internal value (EV) increased by 4.8% year-on-year, despite negative market value adjustments due to rising interest rates [35][46] - The NBV margin improved to 19.5%, up 3.8 percentage points year-on-year, driven by better pricing and distribution strategies [30][34] Insurance Sector Insights - The company’s agent workforce decreased by 4.6% year-on-year to 587,000, but the quality of agents is improving [41][42] - The company is focusing on enhancing the quality of its sales force while expanding its market presence [41] Profitability Forecast and Investment Recommendations - The report anticipates significant net profit growth, with EPS expected to be 4.42, 5.93, and 6.01 for 2026, 2027, and 2028 respectively [2][44] - The fair value for A-shares is estimated at 56.53 CNY and for H-shares at 38.45 HKD, maintaining a "Buy" rating [44][46]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has demonstrated significant results from its product diversification transformation, with dividends achieving high growth for two consecutive years [1] - The company’s net profit attributable to shareholders for 2025 is projected at 154.1 billion yuan, representing a year-on-year increase of 44% [1] - The company’s embedded value (EV) at the end of the period is 1.47 trillion yuan, reflecting a 4.8% increase from the beginning of the year [1] - The forecast for new business value (NBV) growth from 2026 to 2028 is 19.0%, 14.0%, and 13.0% respectively, with corresponding EV growth of 11.4%, 11.9%, and 11.9% [1] Summary by Relevant Sections Financial Performance - Total premium income for 2025 reached 729.9 billion yuan, a year-on-year increase of 8.7%, driven primarily by high growth in new business from the bancassurance channel [2] - The company achieved an NBV of 45.8 billion yuan in 2025, up 36% year-on-year, with a notable improvement in value rate due to adjustments in product structure [2] - The company’s investment assets reached 7.42 trillion yuan in 2025, a 12% increase year-on-year, with a significant increase in equity allocation [3] Profitability and Valuation - The projected net profit for 2026 is 168 billion yuan, with a year-on-year growth of 9.0%, and for 2027, it is expected to be 177.6 billion yuan, growing by 5.8% [4] - The price-to-embedded value (P/EV) ratios for 2026, 2027, and 2028 are projected to be 0.68, 0.61, and 0.54 respectively, indicating a favorable valuation trend [4] - The company plans to distribute a dividend of 0.856 yuan per share for the year, reflecting a 32% increase year-on-year, with a static dividend yield of 2.2% at the current stock price [1]

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of China Life Insurance, with current prices at 39.49 RMB and 27.36 HKD respectively [1]. Core Insights - In 2025, China Life Insurance achieved an operating revenue of 615.68 billion RMB, a year-on-year increase of 16.5%. The net profit attributable to shareholders reached 154.08 billion RMB, up 44.1% year-on-year [4]. - The new business value (NBV) grew by 35.7% year-on-year to 45.75 billion RMB, indicating robust growth in new business despite a slight slowdown in the growth rate compared to previous quarters [6][7]. - The company’s total investment assets reached 7.4 trillion RMB, with a significant increase in stock assets, which rose by 66.7% year-on-year [6]. Financial Performance - The net investment yield was 3.0%, down 0.4 percentage points year-on-year, while the total investment yield increased by 0.6 percentage points to 6.1% [7]. - The company’s return on equity (ROE) was 27.8%, an increase of 6.2 percentage points year-on-year, reflecting improved profitability [4]. - The dividend per share was 0.856 RMB, a 31.7% increase year-on-year, with a payout ratio of 15.7%, down 1.5 percentage points [4]. Business Development - The company is focusing on marketing system reforms, with a total sales force of 638,000, a decrease of 4.2% year-on-year. However, the quality of the sales force is improving, with a 40% increase in high-performing agents [4]. - The proportion of floating income-type business in the first-year premium has approached 50%, indicating a successful transformation in product structure [5][6]. - The company is actively exploring innovations in the health and elderly care sectors, which are expected to further enhance its core insurance business [7]. Future Projections - The report forecasts a continued growth trend in new business value for 2026, with adjusted net profit estimates for 2026 and 2027 at 161.3 billion RMB and 174.3 billion RMB respectively [7]. - The projected operating revenue for 2026 is 651.3 billion RMB, with a growth rate of 5.78% [9].

Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Insights - The company is expected to achieve significant growth in both profit and value by the end of 2025, with projected revenue of 615.68 billion yuan, a year-on-year increase of 16.5%, and a net profit of 154.08 billion yuan, reflecting a 44.1% growth [1] - The New Business Value (NBV) has shown strong growth, reaching 45.75 billion yuan in 2025, a substantial increase of 35.7%, marking the highest growth rate since 2017 [2] - The company has significantly increased its equity asset allocation, with the proportion of stocks and funds rising from 12.18% at the end of 2024 to 16.89% by the end of 2025, leading to a total investment return rate of 6.09%, up by 59 basis points year-on-year [3] Financial Performance and Forecast - The company forecasts revenue growth from 528.57 billion yuan in 2024 to 615.68 billion yuan in 2025, with a projected net profit increase from 106.94 billion yuan to 154.08 billion yuan during the same period [4] - The diluted earnings per share (EPS) are expected to rise from 5.45 yuan in 2025 to 6.87 yuan by 2028, with corresponding price-to-earnings (P/E) ratios decreasing from 7.21 to 5.72 [6]

Investment Rating - The report maintains a "Strong Buy" investment rating for China Life Insurance [2] Core Insights - The company reported a net profit attributable to shareholders of 154.08 billion, a year-on-year increase of 44.1% for 2025, with a total investment return rate of 6.1%, up by 0.6 percentage points [1][5] - The new business value (NBV) for life insurance reached 45.75 billion, reflecting a year-on-year growth of 35.7% [5] - The company is increasing its equity investments, with total investment assets growing to 74,237.05 billion, a 12.3% increase from the beginning of the year [5] Summary by Sections Financial Performance - The company achieved a net profit of 154.08 billion in 2025, with a quarterly breakdown showing Q4 at -13.73 billion, while Q1, Q2, and Q3 had growth rates of +39.5%, -31.2%, and +91.5% respectively [5] - The total investment income was 387.69 billion, a year-on-year increase of 25.8% [5] - The company’s net assets attributable to shareholders increased by 16.8% to 595.21 billion by the end of 2025 [5] Business Growth - The NBV for life insurance was 45.75 billion, with new single premiums at 234.08 billion, a 9.3% increase year-on-year [5] - The NBV margin improved to 19.5%, up by 3.8 percentage points, driven by product structure optimization [5] - The company’s individual insurance NBV grew by 25.5%, while the sales force decreased by 4.6% [5] Investment Strategy - The company is dynamically optimizing its asset allocation, increasing equity investments significantly, with equity investment scale exceeding 1.2 trillion, up by over 450 billion from the start of the year [5] - The proportion of stocks and funds in the investment portfolio rose from 12.2% to 16.9% [5] - The report anticipates net profits for 2026-2028 to be 135.21 billion, 151.31 billion, and 167.11 billion respectively, with growth rates of -12%, +12%, and +10% [5]

Investment Rating - The investment rating for the company is "Buy" [6][5] Core Insights - The company reported a net profit of RMB 154.1 billion for 2025, representing a year-on-year growth of 44%, although this was below previous expectations of RMB 171.8 billion due to investment volatility [1] - The total investment return rate for 2025 reached 6.09%, an increase of 59 basis points year-on-year, primarily driven by strong equity market performance [1] - The New Business Value (NBV) grew by 35.7% year-on-year in 2025, with individual insurance and other channels increasing by 25.5% and 169.3% respectively, mainly driven by the bancassurance channel [1][2] - The company’s dividend per share (DPS) for 2025 was RMB 0.856, a 32% increase year-on-year, with a dividend payout ratio of 16%, slightly down from the previous year [1] Summary by Sections Financial Performance - The company achieved a net profit of RMB 154.1 billion in 2025, with a year-on-year growth of 44% [1] - The NBV for 2025 increased by 35.7%, with a notable acceleration in growth in the second half of the year [2] - The total investment income for 2025 was RMB 383.7 billion, reflecting a 29.01% increase year-on-year [10] Investment and Asset Allocation - The company significantly increased its allocation to secondary equity assets, with the proportion of stocks and funds rising by 4.7 percentage points to 16.9% [4] - The company’s investment performance improved, with a 30% increase in investment income driven by rising equity asset prices [4] Future Projections - The EPS estimates for 2026, 2027, and 2028 have been adjusted to RMB 3.89, RMB 4.14, and RMB 4.55 respectively, reflecting a downward revision of 7% and 13% for 2026 and 2027 [5] - The target price for the company's A/H shares has been raised to RMB 53 and HKD 32, respectively, from previous estimates of RMB 52 and HKD 29 [5]